COMPASS Therapeutic Notes on the Management of Dementia

In this issue	
	Page
Introduction: Background Symptoms & Diagnosis	1
Prevention Strategies	6
Management of Cognitive Symptoms of Dementia	7
Management of Behavioural and Psychological Symptoms of Dementia (BPSD)	11

Glossary of terms	
RCT	Randomised Controlled Trial
Visuoperceptual difficulties	Vision difficulties that can result in a variety of 'visual mistakes' (including illusions, misperceptions, misidentifications and sometimes even hallucinations)
Cognitive Behavioural Therapy	A specific form of psychotherapy. It aims to help people to change how they think ('cognitive') and what they do ('behaviour')
Lewy bodies	Spherical protein deposits found in nerve cells
CSM	Committee on Safety of Medicines (the predecessor to the Commission on Human Medicines)
Akathisia	Unpleasant feeling of restlessness with involuntary body movements
Dystonia	Abnormal muscle tone resulting in muscular spasm and abnormal posture
Neuroleptic Malignant Syndrome	A potentially life-threatening condition characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels

Successful completion of the assessment questions at the end of this issue will provide you with <u>2 hours</u> towards your CPD/CME requirements.

Further copies of this and any other edition in the COMPASS Therapeutic Notes series, including relevant CPD/CME assessment questions, can be found at:

- <u>www.medicinesni.com</u> or
- www.hscbusiness.hscni.net/services/2163.htm

<u>GPs</u> can complete the multiple choice questions on-line and print off their CPD/CME certificate at <u>www.medicinesni.com</u>

Pharmacists should enter their MCQ answers at www.nicpld.org

Introduction: Background, Symptoms & Diagnosis

What is dementia?

Dementia is a progressive degenerative neurological syndrome, used to describe a collection of symptoms.¹⁵ It is characterized by cognitive decline, impaired memory, reduced reasoning and communication skills, and a gradual loss of skills needed to carry out daily activities.^{9,15} Dementia is not part of normal ageing; it is caused by

structural and chemical changes in the brain as a result of physical diseases such as Alzheimer's disease and cerebrovascular disease.¹⁵

Other functions are also affected, including changes to mood, personality and social behaviour.⁹ See later for Behavioural and Psychological Symptoms of Dementia (BPSD).

This publication will discuss mainly the management of **Alzheimer's disease**, as vascular dementia is managed by the modification of vascular risk factors.

Incidence of dementia?

Approximately 1.3% of the UK population suffer from dementia.⁶ Incidence rises with increasing age: about 1 in 20 over 65 year olds have dementia but by the age of 80 from about 1 in 5 will have some degree of dementia.^{9,11} With an ageing population (and improved

rate of diagnosis) the number of people with dementia is expected to rise.⁶

Early onset dementia (under the age of 65 years) is comparatively rare, accounting for 2.2% of all people with dementia in the UK.¹⁵

Dementia is more common in women. This is partly due to women living longer than men: the average life expectancy for a woman in Northern Ireland is currently 81 years, compared to 76 years for a man.^{2,16}

Costs of dementia care in Northern Ireland

With life expectancy increasing and an increasingly ageing population, rates of dementia are expected to increase. In Northern Ireland it is estimated that as many as 18-19,000 of the population suffer from dementia. This figure may rise to approximately 60,000 by 2051.² This represents a major public health and societal issue, with further pressure on care and support services and on those who provide informal care.² This is recognised in the **Improving Dementia Services In Northern Ireland, a Regional Strategy, 2011**. The strategy addresses a wide range of issues in the management of dementia and includes an action plan to improve and redesign services.²

TABLE ONE: MAPPING THE DEMENTIA GAP IN NORTHERN IRELAND Numbers of people with dementia in 2012 in local health areas and Strategic Health Authority areas¹²

Numbers of people with dementia in 2012 in local health areas and Strategic Health Authority areas				
Area name	Estimated number of	Percentage of people	Number of people	Best-worst overall
	people with dementia	with dementia with a	without a	ranking
	(diagnosed and	diagnosis	diagnosis	(1=highest UK ranking,
	undiagnosed)			178=lowest)
Northern Ireland	18862	63%	6980	
Belfast	3846	75.5%	941	1
South Eastern	3929	61.9%	1498	14
Northern	5027	51.4%	2445	52
Southern	3343	63.8%	1209	11
Western	2717	67.4%	887	5

Types of dementia?

Dementia is classified into various subtypes according to the different disease processes involved.⁹ The most common are:

- Alzheimer's disease (present in over 50% of dementia cases)
- Vascular and Mixed dementia* (approx. 27% of dementia cases)
- Dementia with Lewy Bodies (approx. 15% of dementia cases)

Other types of dementia include frontotemporal lobar degeneration, alcohol-related dementia, and dementia related to diseases such as Parkinson's disease, Creutzfeldt-Jacob disease, HIV/AIDs and Huntington's disease.²

*Mixed dementia (both Alzheimer's disease and vascular factors) is commonly seen and is difficult to differentiate clinically.^{2,9,15}

What is the prognosis?

Much individual variability is seen in people with dementia. Median survival with Alzheimer's disease has been estimated at 7.1 years (6.7-7.5 years) while vascular dementia has been estimated at 3.9 years (3.5-4.2 years).²² Increased age and male gender are associated with higher rates of mortality in dementia.⁹⁸

Co-morbid health conditions (which may or may not be related to dementia) often exist, making it difficult to determine the contribution of dementia to mortality.¹⁵ Dementia is however a progressive, terminal disease, which is reflected in the management of the disease.²

Dementia subtype	Explanation
Alzheimer's disease	First diagnosed by German neurologist Alois Alzheimer in 1906. ¹⁵ In Alzheimer's disease changes occur to the chemistry and structure of the brain, causing brain cells to die. The exact cause is unknown. Findings include reduced synthesis of the neurotransmitter acetylcholine and the development of protein plaques and 'tangles' in the brain. ¹⁵
Vascular dementia	Arteries supplying blood to the brain become blocked, leading to small strokes and ischaemic damage in the brain. ⁹ The most common form is subcortical vascular dementia. Sometimes a patient will be stable for several months or years but further deterioration can manifest as subsequent strokes occur. Vascular dementia will affect different parts of the brain and this dictates the resultant symptoms: poor executive function, memory loss, poor concentration, word finding difficulties, mood swings or depression. Some people have hallucinations. Physical problems can develop, such as difficulties with walking or incontinence. It is more common in smokers and patients with heart disease, hypertension, diabetes or high cholesterol. ^{11,15}
Dementia with Lewy Bodies (DLB)	DLB is caused by tiny spherical protein deposits that develop inside nerve cells in the brain, similar to Parkinson's Disease. As such, symptoms often overlap with Alzheimer's disease and Parkinson's disease. The level of confusion can fluctuate, and visual hallucinations are more common. People may also have a tremor, muscle stiffness, experience falls or difficulty with walking. ^{11,15}

CHART ONE: Prevalence of types of dementia in women and men (all ages) in the UK² (taken from the Improving Dementia Services in Northern Ireland Regional Strategy, 2011. Based on the Dementia UK report¹⁵)




TABLE TWO: Dementia Subtypes

Should screening be carried out?

NICE do not recommend routine screening for dementia in the general population.³ However, opportunistic screening should be carried out in patients at increased risk of dementia, e.g. patients with Down's syndrome, post stroke and Parkinson's disease, or with a large number of vascular risk factors.¹

Signs and Symptoms

A deterioration in memory accompanied by functional decline is the principle symptom. Often relatives are concerned about the person's memory or behaviour, but they themselves are not.¹ It is therefore essential to get an account of the person's problems from a close relative or friend.¹⁵

Signs and symptoms are often not specific to dementia.¹ The following are possible signs and symptoms of dementia. If any of the following are reported (by the person or by someone close to them) to be new or deteriorating then an assessment is advisable:¹

Cognitive symptoms

- Memory problems such as forgetfulness, repetitive questioning, difficulty finding names and other words, not knowing common facts.
- Misunderstanding spoken and written communication.
- Disorientation.¹

Difficulties with activities of daily living (ADL)

- Difficulty with orientation, getting lost, loss of driving skills.
- Taking prescribed drugs erratically for example uncharacteristic variations in INR (international normalized ratio) in a person normally taking stable doses of warfarin.
- Forgetting recipes when cooking, neglecting household chores, trouble with shopping, difficulty handling money.
- Neglecting hygiene or self-care, deterioration in personal appearance, or a reduction in social roles.
- Making mistakes at work.¹

Challenging behaviours, psychiatric symptoms, and personality changes

- Withdrawal or apathy
- Loss of motivation
- Depression, agitation, anxiety
- Blunting of emotions and loss of interest, social withdrawal
- Disinhibition, inappropriate friendliness, flirtatiousness
- Suspiciousness, fearfulness, aggression, psychosis (delusions, hallucinations)
- Insomnia
- Restlessness, wandering, agitation, noisiness¹

Neurological symptoms


 Gait disturbances, apraxia (loss of ability to perform learned purposeful movements).

Progression of symptoms

Symptoms of **Alzheimer's disease** tend to change over time as the disease progresses. **GRAPH ONE** illustrates how Alzheimer's disease usually begins with mild memory impairment, gradually progressing through stages of increasing cognitive decline, diminishing functioning, compromised judgment, deterioration in self-care, and eventually inability to manage life independently. In many cases, the course of Alzheimer's disease is complicated further by disturbances in mood and behaviour (see later for Behavioural and Psychological Symptoms of Dementia).⁶⁹

GRAPH ONE: Pattern and Symptoms of Alzheimer's disease over time

(Lovestone and Gauthier, Management of Dementia, 2001)^{23,86}



How is diagnosis made?

There is no simple test to make a diagnosis of dementia. Diagnosis can only be made after a comprehensive assessment, including ³

- History taking
- Review of medication to identify any drugs that may impair cognitive functioning
- Cognitive and mental state examination
- Physical examination
- Neuroimaging

Who should make the diagnosis?

NICE clinical guidance currently recommends that the diagnosis of dementia (including subtype) should be confirmed by a specialist.³ GPs can make an informed estimate of likelihood, and before referral start exploring and addressing the concerns of the person and their family or carer, and ensuring that people with dementia are given the opportunity to make informed decisions about their care and treatment.¹ GPs are generally the first port of call for people worried about their health and therefore it is important that GPs have a good knowledge of dementia and be aware of the importance of **early diagnosis**.²

The possibility of GPs taking on a more central role in the diagnosis and management of more routine and typical cases of dementia is being explored. This is in line with the concept of providing increased access to a more timely diagnosis, with better continuity of care and person-centred treatment reviews.⁸⁷

Benefits of early diagnosis

An objective of the Dementia Strategy is to increase the numbers of people receiving a good quality early diagnosis of dementia. Diagnosis of dementia is often delayed for many reasons, including a reluctance to seek help for a condition that the person or their family perceive as stigmatising and untreatable.¹ Early diagnosis is however very important as it allows the person with dementia to:

- Exclude any other potential causes of the symptoms (e.g. depression, stress, delirium, adverse effects of medicines).
- Receive interventions which may slow the progression of the disease: start treatment early with AChE inhibitors.
- Receive care and support which may improve their quality of life and make choices and plans for the future, with their family, while the condition still permits this.
- Ensure appropriate intervention and support which is tailored to individual needs of the person.²

What is Mild Cognitive Impairment (MCI)?

Mild Cognitive Impairment (MCI) is a term used to describe a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills. The changes are not severe enough to interfere with daily life or independent function. Therefore, a person with MCI does not meet diagnostic criteria for dementia. Those with MCI have an increased risk of eventually developing Alzheimer's or another type of dementia.

The conversion rate from MCI to Alzheimer's is 10 to 20% each year; over 50% of people with MCI later develop dementia.^{3,90} Therefore not all people with MCI get worse and some eventually get better.^{1,89} **Consider referring people who show signs of MCI for assessment by Memory Assessment Services to aid early identification of dementia.**

Differential diagnosis

It is important to exclude other conditions or illnesses that can cause memory loss, including depression, alcohol problems and some physical illnesses with organic brain effects.¹⁵ See **TABLE THREE**. Investigations should be carried out to exclude other causes:^{1,3}

- A basic dementia screen at the time of presentation including:
 - Routine haematology
 - Biochemistry tests (electrolytes, calcium, glucose, and renal and liver function)
 - Thyroid function tests
 - serum vitamin B12 and folate levels
- A midstream urine test (if delirium is a possibility)
- Investigations such as chest X-ray (to rule out a chest infection) or electrocardiogram (ECG) (if a cardiovascular problem is suspected) may be considered, as determined by clinical presentation.³

When the onset of memory problems is **sudden**, a vascular event is often considered.¹ When the onset is **sub-acute**, an infection (or other cause of acute confusion/delirium) is likely, especially if there is alteration in level of consciousness.¹

What cognitive function tests are used?

Cognitive function tests are used <u>alongside</u> other investigations in determining whether a diagnosis of dementia is likely. NB – dementia is graded on overall severity, i.e. a composite of cognition, behaviour and activities of daily living (they don't always correlate).³ Cognitive testing is carried out using a standardised instrument, such as:³

- Mini Mental State Examination (MMSE)
- General Practitioner Assessment of Cognition (GPCOG)*
- Addenbrooke's Cognitive Examination
- Montreal Cognitive Assessment (MoCA)
 Alzheimer's Disease Assessment Scale (ADAS)
- 6-Item Cognitive Impairment Test (6-CIT)
 7-Minute Screen.

* The General Practitioner Assessment of Cognition (GPCOG) tool has been designed for the primary care setting.

Mini Mental State Examination (MMSE)

MMSE is the most commonly used test to assess cognitive function. However, due to copyright issues with MMSE, some clinicians are looking at alternative tests in assessing cognition (see above). MMSE is essentially a series of questions and tests, each of which scores points if answered correctly. A maximum of 30 points is possible.¹⁵

Severity of dementia is frequently defined by Mini Mental State Examination (MMSE) score:²⁴

- Mild Alzheimer's disease: MMSE 21-26
- Moderate Alzheimer's disease: MMSE 10-20
- Moderately severe Alzheimer's disease: MMSE 10-14
- Severe Alzheimer's disease: MMSE less than 10 $^{\rm 24}$

Factors that may affect performance in these tests, such as educational level, skills, prior level of functioning and attainment, language, sensory impairment, psychiatric illness and physical or neurological problems must be taken into account.³

Stages of dementia

The progression of **Alzheimer's disease** may be divided into three stages: early, mild to moderate and severe. This is illustrated in **GRAPH TWO**. This is based on MMSE scores. The symptoms change over time, starting with cognitive symptoms, progressing to loss of activities of daily living (ADL) and behavioural symptoms.

The progression of **vascular dementia** tends to follow a step-wise course with periods of stability (although the actual course is difficult to predict).

GRAPH TWO: The Progress of Alzheimer's disease (Feldman H, Gracon S. Clinical Diagnosis and Management of Alzheimer's disease. 1996:239-253)^{86,95}




TABLE THREE: Differential Diagnosis of Dementia

Condition	Difference to dementia
Normal	Normal ageing is associated with a mild decline in cognitive function. In dementia, the cognitive
ageing	impairment is more severe and global, and results in clinically significant functional disability. Lapses of
ageing	memory can occur due to physical illness or stress. If in doubt about the significance of memory lapses,
	offer to review in 3 months. ¹
Mild	In mild cognitive impairment the person notices memory problems. However, the memory problems do
cognitive	not interfere with activities of daily life or social and occupational functioning, and general cognition is
impairment	preserved. In dementia the person is not always aware of their symptoms. ¹
Depression	It is important to recognise depression because it is common, treatable, and can present with features
Depression	similar to those of dementia.
	In comparison with dementia, the onset of depressive symptoms may be more rapid. Depression may
	become evident over a few weeks or months, while the symptoms of dementia may have been present
	for several months by the time the person presents to the healthcare professional.
	Depression can co-exist with dementia, and if both are new diagnoses, depression should usually be
	treated and controlled before managing the dementia. ¹
Delirium/	It is important to recognise delirium (or acute confusional state) because it is common and treatable.
acute	In comparison with non-vascular dementia, the onset of symptoms are more rapid (over a few hours or
confusional	days).
state	Symptoms generally worsen at night, with increased confusion, disorientation, and emotional disturbance
Sidie	(fear, irritability, aggression). Paranoia and hallucinations (visual or auditory) are common.
	Common causes of delirium include chest infection, urinary tract infection, adverse effects of drugs,
	biochemical imbalance, and alcohol withdrawal.
	Delirium can co-exist with dementia, and if both are new diagnoses, delirium should usually be treated
	and controlled before managing the dementia. ¹
Parkinson's	Parkinson's disease dementia is diagnosed if the motor symptoms appear more than 12 months before
disease	the cognitive symptoms.
versus	Dementia with Lewy Bodies is diagnosed when someone has symptoms of dementia before or at the
Lewy body	time of developing Parkinson's disease-like symptoms. ¹⁵
dementia	
Drugs –	Psychoactive drugs
adverse	Psychoactive drugs are the commonest causes of drug-induced cognitive impairment and delirium (e.g.
effects and	benzodiazepines, antidepressants, analgesics, anticonvulsants, antipsychotics and anti-Parkinsonian
drug	drugs).
interactions	
	Non-psychoactive drugs
	Non-psychoactive drug-induced confusion is harder to spot as they are often peculiar to the individual
	and the diagnosis is easily missed. Examples include proton pump inhibitors, digoxin, calcium
	antagonists, corticosteroids and some antibiotics. ¹
	Anticholinergic burden
	Drugs with anticholinergic activity can increase the risk of cognitive impairment and delirium in those
	aged over 65 years. A drug may be given an anticholinergic burden (ACB) score on the basis of the
	strength of its anticholinergic activity. Drugs with a high ACB score include tricyclic antidepressants,
	antipsychotics such as quetiapine and olanzapine (risperidone has a slightly lower ACB score), and
	antimuscarinic drugs used for urinary incontinence/frequency, e.g. oxybutynin, tolterodine, darifenacin
	(alpha blockers such as tamsulosin would not be included under anticholinergics).
	Effects are additive: individuals who take multiple medicines with individually modest anticholinergic
	activity may also have increased risk of adverse effects. Therefore the combined anticholinergic burden
	should be taken into account.91-94
	For further information on the anticholinergic burden please refer to HSCB Medicine Safety Alert:
	http://www.hscboard.hscni.net/medicinesmanagement/Medicines%20Safety%20Alerts/011%20No11%20
	Anticholinergic%20Syndrome%20-%20October%202012%20-%20PDF%20395KB.pdf
Following di	agnosis

Following diagnosis

People who are assessed for possible dementia should be asked whether they wish to know the diagnosis and with whom it should be shared.³

At the time of diagnosis, and regularly afterwards, medical and psychiatric co-morbidities, including depression and psychosis should be assessed.³ Getting a diagnosis of dementia is often distressing and the way in which information, advice and support are offered can make a huge difference in helping people cope with the diagnosis.²

Voluntary agencies such as **Alzheimer's Society** (<u>www.alzheimers.org.uk/</u> helpline: 028 9066 4100) and **Age NI** (<u>www.ageuk.org.uk/northern-ireland</u>; advice line: 0808 808 7575) can be extremely useful support networks.

Written information should be provided to the person with dementia and their family about:

- Signs and symptoms
- Course and prognosis
- Treatments
- Local care and support services
- Support groups
- Sources of financial and legal advice and advocacy
- Medico-legal issues, including driving
- Local information sources, including libraries and voluntary organisations.

Prevention Strategies

Is dementia preventable?

According to the Improving Dementia Services in Northern Ireland Strategy, delaying the onset of dementia in the population by five years could halve its prevalence.² Therefore it is important that steps are taken to reduce the risk of dementia.

What are the main risk factors?

Not all risk factors will be modifiable and others will be specific to particular types of dementia.² More research is needed to determine which risk factors play the greatest role in the development of dementia, and whether intervening to modify these risk factors will impact significantly on the development of dementia.²

Until the evidence in relation to risk factors is determined, large scale promotion of prevention

TABLE FOUR: Non-modifiable Risk Factors

strategies to the general public cannot be adopted. However, promotion of healthy lifestyle choices and avoidance of potential risk factors to the general population will obviously have general health benefits and may reduce or delay the onset of dementia.²

NICE are currently developing public health guidance on delaying the onset of disability, frailty and dementia in later life. The guidance will focus on preventive approaches that may be adopted in mid-life. It is expected to be issued February 2015.⁸⁸

Essentially what is good for general health and cardiovascular health is also likely to be good for dementia: staying healthy both mentally and physically.

Risk factor	Perception of risk
Age	Advancing age is the biggest risk factor for dementia. ²
Gender	Women are slightly more likely to develop Alzheimer's disease than men (even discounting for increased life expectancy). ¹² The reasons for this are unclear. Rates of vascular dementia are higher among men. ²
Genetics	The role of genetics is not fully understood. A number of genes have been identified that do not directly cause dementia but are thought to affect a person's risk of developing the disease, e.g. the gene apolipoprotein E has been shown to be a susceptibility gene, i.e. it does not predict that dementia will develop but if there is a dementia onset, then it will come on earlier. ¹² It is also possible to inherit genes that can directly cause dementia, i.e. there is a clear inheritance of dementia from one generation to the next. These are much rarer and include examples such as Huntington's disease and familial Alzheimer's. ¹²
Medical history	A Medical or Family History of Cardiovascular Disease Conditions that affect the heart, arteries or blood circulation all significantly affect a person's chances of developing dementia, particularly vascular dementia. Examples include: diabetes, heart problems, atrial fibrillation, and stroke. ² Stroke is a major risk factor for dementia – it is thought that a history of stroke doubles the risk of dementia in the older population. ² Some factors affecting cardiovascular disease are modifiable – see Modifiable Risk Factors.
	Depression Patients with either a history of depression or who experience depression later in life are at a likely increased risk of dementia. Sometimes depression can be an early symptom of dementia. Management of depression in Alzheimer's disease is discussed later. ¹²
	Repeated Head Injuries It has been suggested that deposits that form in the brain as a result of the injury may be linked to the onset of dementia. Professional boxers can develop a form of dementia known as dementia pugilistica. ¹²
	Learning Disability The ageing process for people with learning disability begins much earlier. People with Down's syndrome have high rates of Alzheimer's type dementia. ²
	Other Medical Conditions Examples include: Parkinson's disease, multiple sclerosis, chronic kidney disease and HIV. ¹²

TABLE FIVE: Modifiable Risk Factors

Risk factor	Perception of risk
Smoking	Risk factor for both Alzheimer's and vascular dementia. Likely due to harmful effects on the
-	heart, lungs and vascular system, including the blood vessels in the brain.
Alcohol	Risk is linked to excessive consumption. Drinking within the recommended limits is unlikely to
	increase the risk of dementia. Some research suggests that drinking light to moderate amounts
	of alcohol may actually protect against dementia.
	Alcohol-related Brain Injury (Korsakoff's syndrome) is caused by a lack of vitamin B1. It is seen
	in people who regularly drink excessive amounts of alcohol over a long period of time. It is not
	strictly a dementia, but is characterised by memory loss. ¹²
Obesity	Obesity in mid-life may be associated with an increased risk of Alzheimer's in later life.
	Obesity is also a risk factor for diabetes, heart disease and stroke and, therefore, vascular

	dementia.
Hypertension	In mid-life this has been shown to be a risk factor for the development of both vascular
	dementia and Alzheimer's.
Raised cholesterol	Has been associated with the development of Alzheimer's. It is also a risk factor for
	cardiovascular disease, and therefore, vascular dementia.
Raised	Raised homocysteine levels in the blood and low levels of folate may be associated with heart
homocysteine levels	disease, stroke and an increased risk of dementia. ²
Benzodiazepines	Benzodiazepines are associated with cognitive impairment. Use of benzodiazepines (or similar
	drugs) may also be associated with subsequent risk of development of dementia. Clinicians
	should ensure that any new prescriptions are in line with NICE and MHRA advice and reserved
	for the short-term relief of anxiety or insomnia that is severe, disabling and causing
	unacceptable distress to patients. Other interventions such as cognitive behavioural therapy
	should be considered as first line for anxiety and insomnia. 56,57

How significant is lifestyle in the development of dementia?

In addition to addressing possible risk factors for dementia, consideration should be given to adopting lifestyle choices that may actively protect against the development of dementia.

Diet

A healthy and balanced diet that enables a person to maintain a normal body weight is recommended. A Mediterranean diet with a high proportion of fish, fruit, vegetables and unsaturated fat, and a low proportion of dairy products, meat and saturated fat will help to manage cholesterol and blood pressure.¹² Fresh fruit and vegetables contain many vitamins and antioxidants, which may help prevent dementia. In addition to this, low levels of vitamin D are associated with an increased risk of developing dementia. Good dietary sources of vitamin D include eggs and oily fish. Fatty acids also found in oily fish may also help reduce the risk of developing dementia.¹²

Exercise

Exercise helps to protect against many conditions, including dementia. Regular physical exercise helps to keep the cardiovascular system healthy. At least 30 minutes of moderate intensity exercise, five times a week is recommended.¹² Participation in physical activity for 20 to 30 minutes twice a week in mid-life has been shown to be associated with a lower risk of dementia in later life.¹²

Mentally challenging activities

E.g. reading, learning, puzzles, playing a musical instrument, board games, dancing.

Research suggests that people who take part in mental activities are less likely to develop dementia, but this requires further research.² It is thought that mental activity increases the brain's ability to cope with (and compensate for) damage to the brain and hence symptoms of dementia are delayed.¹² 'Brain training' games may be more important over the age of 60 in preventing or delaying dementia than when used in younger people to 'improve mental fitness'.¹²

Social activity

Research suggests that people who are more socially active have a slightly reduced risk of developing dementia.¹²

Interventions for prevention?

NICE specify that the following are <u>not</u> used for primary prevention of dementia: statins, hormone replacement therapy, vitamin E and NSAIDs.³ For the secondary prevention of dementia, vascular and other modifiable risk factors should be reviewed in people with dementia.³

Any evidence for alternative therapies?

Alternative therapies that have been tried for primary prevention of dementia include ginkgo biloba⁵⁴ and omega 3 fish oils²⁷. To date, there is inconclusive evidence that either is effective. A Cochrane review in 2012 reported that direct evidence of omega 3 fish oils in reducing the incidence of dementia is lacking; the available trials showed no benefit of omega 3 fish oil supplementation on cognitive function in cognitively healthy older people. A 2009 Cochrane review reported that there is no conclusive evidence on the efficacy of Ginkgo biloba for dementia or cognitive impairment. The review found that available evidence is inconsistent and unreliable.⁵⁴

Management of Cognitive Symptoms of Dementia

Aim of treatment

For the majority of dementias, it is not possible to alter the progressive course of the disorder. The aims of treatment are therefore to promote independence, maintain function and treat symptoms including cognitive, non-cognitive, behavioural and psychological symptoms.^{2,15} Treatment should be person centred, respecting the individual patient's circumstances. Offering appropriate support services can make a significant difference to the lives of people with dementia and their caregivers.^{2,15}

Non-drug treatment

Giving people with dementia the opportunity to take part in activities that are **suited to their capabilities** has been shown to improve quality of life. Attention must be focused on the whole person and may include:

- Modifying environments
- Simplifying tasks
- Establishing structure and routine
- Practising tasks through repetition
- Using effective cueing and communication strategies
- Assistive technology
- Skills training
- Education of family and caregivers ²

What about Medical Foods?

There are currently three medical foods that claim to offer symptomatic benefits for people with Alzheimer's

disease: Axona[®], CerefolinNAC[®] and Souvenaid[®]. They contain ingredients such as omega fatty acids and phospholipids. More extensive studies are needed to provide clearer information on the benefit of each product. To date, most studies have been conducted in patients with mild Alzheimer's disease and it is not possible to generalise results to all stages of Alzheimer's disease.⁷² There is no evidence that these products benefit people with moderate Alzheimer's disease or in those already taking drugs for Alzheimer's disease.

Cost of Souvenaid[®]: £3.49 per 125mL drink.

Drug Treatments

Vascular dementia

The major difficulty clinically is that in older people vascular disease and Alzheimer's disease commonly co-exist. Pure vascular dementia is quite rare. Treatment of vascular dementia focuses on controlling underlying risk factors for cardiovascular disease.⁹ There are no medicines licensed in the UK for vascular dementia.⁹ Trials to investigate the benefit of acetylcholinesterase (AChE) inhibitors or memantine in vascular dementia have been inconclusive.⁵⁶ As it is often difficult to diagnose dementia subtypes, it might explain why AChE inhibitors do not always produce consistent results – in probable vascular dementia case.⁹

Dementia with Lewy Bodies (DLB)

The effect of AChE inhibitors in DLB remains unclear.⁷⁹ Rivastigmine is licensed for mild to moderately severe Alzheimer's dementia and mild to moderately severe dementia in patients with idiopathic Parkinson's disease dementia.⁷³ Due to clinical similarities between DLB and dementia in patients with Parkinson's disease, rivastigmine would seem a logical choice of AChE inhibitor for patients with DLB. There is some evidence that rivastigmine can reduce some behavioural problems in DLB – see later.

From this point on this section will focus on the management of Alzheimer's disease

Who should initiate drug treatment?

Currently, NICE recommend that only specialists in the care of patients with dementia (that is, psychiatrists including those specialising in learning disability, neurologists, and physicians specialising in the care of older people) should initiate treatment. GPs may continue treatment under Shared Care arrangements. Drugs for dementia are currently amber listed.²⁹

NICE Guidance ³

Mild to Moderate Alzheimer's disease:

One of the three acetylcholinesterase (AChE) inhibitors are recommended as options:

- Donepezil
- Galantamine
- Rivastigmine.

Moderate to Severe Alzheimer's disease:

Memantine is recommended as an option for managing Alzheimer's disease for people with:

- Moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or
- Severe Alzheimer's disease.³

How do AChE inhibitors work?

One theory of the cause of Alzheimer's disease is progressive loss of cholinergic neurons and decreasing levels of acetylcholine in the brain.³⁶ Acetylcholinesterase and butyrylcholinesterase play an important role in the degradation of acetylcholine.³⁷ Therefore inhibitors of these enzymes increase the concentration of acetylcholine at sites of neurotransmission.^{9,24}

Which AChE inhibitor to choose?

Initial choice is normally the AChE inhibitor with the lowest acquisition cost. However, an alternative AChE inhibitor could be prescribed if considered appropriate when taking into account side effect profile, expectations about adherence, medical co-morbidity, possibility of drug interactions and dosing profiles. Few head-to-head studies have been published and there have been differences in both populations studied and trial design.⁹ However, to date, similar efficacy and tolerability between AChE inhibitors is assumed.⁹ Donepezil has been reported more likely to be prescribed at an effective dose compared to rivastigmine or galantamine, perhaps due to a shorter titration schedule and better tolerability.⁴² All three AChE inhibitors are available generically as oral formulations.⁷⁴

Dementia drug	Strength and formulation	Brand name	Cost (28 days)
Donepezil	5mg tablets	Non-	£2,19
	511.5 1.51515	proprietary	
		Aricept [®]	£59.85
	10mg tablets	Non-	£2.89
	. enig tablete	proprietary	~
		Aricept [®]	£83.89
	5mg	Non-	£36.49
	orodispersible	proprietary	
	tablets	Aricept	£59.85
		Evess®	
	10mg	Non-	£50.58
	orodispersible	proprietary	
	tablets	Aricept	£83.89
		Evess®	
Galantamine	8mg MR	Acumor [®] XL	£49.26
	capsules	Galsya [®] XL	£51.88
		Reminyl [®] XL	£51.88
	16mg MR	Reminyl [®] XL Acumor [®] XL	£61.65
	capsules	Galsya [®] XL	£64.90
		Reminyl [®] XL	£64.90
	24mg MR	Acumor [®] XL	£75.81
	capsules	Galsya [®] XL	£79.80
		Reminyl [®] XL	£79.80
Rivastigmine	1.5mg	Non-	£66.51
Ū	capsules	proprietary	
		Exelon®	£66.51
	3mg capsules	Non-	£66.51
		proprietary	
		Exelon®	£66.51
	4.5mg	Non-	£66.51
	capsules	proprietary	
		Exelon®	£66.51
	6mg capsules	Non-	£66.51
		proprietary	
		Exelon®	£66.51
	4.6mg/24hr	Exelon®	£77.97
	patch		(30
			days)
	9.5mg/24hr	Exelon®	£77.97
	patch		(30
			days)
Memantine	10mg tablets	Ebixa®	£34.50
	20mg tablets	Ebixa®	£69.01

TABLE SIX: Cost of dementia drugs for 28 days 74

Practices are asked to **prescribe generically** so savings can be made as soon as the generic price drops. Also, consider the need before prescribing an orodispersible donepezil formulation.

How is response to treatment determined?

It is difficult to predict how an individual will respond to treatment.⁹ Clinical effects are measured in terms of cognition, function, behaviours and global assessments.³ Patient response can be described as one of three ways:

- Non-responders continue to decline at the anticipated rate (33.3% of patients over six months)
- Non-decliners neither improve significantly or decline further (33.3% of patients over six months)
- Improvers improve to a clinically significant extent* (33.3% of patients over six months)

* Show a > 4-point improvement on ADAS score.⁶

Benefit is assessed by repeating the cognitive assessment at **around 3 months**. Drugs for dementia should be discontinued in those thought not to be responding. Many specialists repeat the cognitive assessment 4 to 6 weeks after discontinuation to assess deterioration; if significant deterioration occurs during this short period, consideration should be given to restarting therapy.⁷⁴

Duration of treatment?

Patients who continue on treatment should be reviewed regularly using cognitive, global, functional and behavioural assessment.³ Studies have reported benefits of continued donepezil therapy as disease progresses (with respect to

cognitive and functional outcomes).^{103,104}

Stopping medicines in late stages for a patient who is at home could result in hospitalisation of the patient. In the later stages of Alzheimer's disease, AChE inhibitors and memantine are no longer used as a means of reducing decline in memory and cognitive functions (as these functions are no longer viable). Instead their role is to support basic psychomotor processes required to help caregivers deliver basic care involving feeding, dressing, and bathing, including the processes of movement, swallowing, and functional communication. The benefits may also extend to reducing antipsychotic usage.⁸⁰

In patients progressing to very advanced dementia, the overall benefit of these agents should be assessed and consideration given to discontinuation.²⁹ It may be easier to discontinue medicines in later stages if patient is in a care home and will therefore be supervised and monitored. At this stage the goal of treatment is palliation and comfort.⁸⁰

Is it worthwhile switching between AChE inhibitors?

Usually, no, as AChE inhibitors have similar efficacy. It *may* be worthwhile switching to another AChE inhibitor if the patient fails to respond to the initial AChE inhibitor, as failure to respond to one AChE inhibitor does not necessarily mean that a patient will not respond to another. The same applies for tolerability: it may be worthwhile switching to another AChE inhibitor if the first option is not tolerated⁹ (NB – tolerability appears to be related to speed of dose titration; more adverse effects are seen during titration).⁹

Switching AChE inhibitors is not recommended in patients who show loss of benefit several years after initiation of treatment.⁸¹

Rivastigmine patches are associated with a lower incidence of GI adverse effects than oral rivastigmine preparations and so may be a more appropriate choice in some patients.⁴³

Another reason for changing therapy is if the working diagnosis is changed: patients may sometimes be switched to rivastigmine if the diagnosis is changed from Alzheimer's disease to Dementia with Lewy Bodies (it can take up to 18 months for diagnosis to be confirmed).




TABLE SEVEN: Starting and maintenance doses of
acetylcholinesterase inhibitors ⁷⁴

AChE inhibitor	Starting dose	Maintenance dose
Donepezil	5mg daily	5 to 10mg daily
Galantamine	8mg daily	16 to 24mg daily
Rivastigmine	1.5mg twice daily	3 to 6mg twice daily

Does donepezil have to be given in the evening? The SPCs specify that donepezil should be given in the evening just prior to retiring. This is to reduce the risk of gastrointestinal side effects: the maximal possible rise in acidity and motility occurs 2 to 3 hours after the tablet is ingested – a time when the majority would be asleep.

However if sleep disturbances are noted, particularly vivid nightmares, then a shift to morning dosing often resolves those problems. The time of dosing may therefore be chosen based on individual tolerability.⁶⁶

If switching, withdraw gradually or direct switch?

This will be on specialist advice only. A direct switch is usually recommended rather than a gradual withdrawal. This is because the benefits of treatment with AChE inhibitors are rapidly lost when drug administration is interrupted and may not be fully regained when drug treatment is initiated.^{38,39} A faster titration may be adopted.^{41,80,81}

In the event of marked adverse events, switching AChE inhibitors can be suggested, but (depending on the side effect) there should be resolution of symptoms before initiating the second agent.⁸¹

What about combination treatment?

Currently NICE do not recommend combination treatment of memantine with an AChE inhibitor.³ However, in practice, memantine is often added in to existing AChE inhibitor therapy. For patients with moderate to severe Alzheimer's disease, memantine is usually initiated once patients have been maintained on stable AChE inhibitor therapy. This is often for management of behavioural symptoms, particularly agitation³ (as per NICE – see BPSD later). Studies on the long term effects of combination AChE inhibitor plus memantine therapy have demonstrated a slowing of both cognitive decline and functional decline (compared with monotherapy or no therapy)⁵⁰ and a delay in nursing home placement.⁵¹

Adding memantine to an AChE inhibitor appears to be well tolerated.^{9,47-49} In terms of drug interactions, no pharmacokinetic or pharmacodynamic interactions have been found between donepezil and memantine or galantamine and memantine.^{52,53} Patients who are established on an AChE inhibitor should <u>not</u> have this treatment stopped when memantine is prescribed as a dramatic decline in functioning is seen which may not be fully regained when restarted.

Don't stop established AChE inhibitor therapy
 A dramatic decline in functioning is seen when drug
 administration is interrupted and may not be fully
 regained when drug treatment is initiated.


CHART TWO: Summary of treatment options for dementia (Taken from Northern Health and Social Care Trust algorithm)

How does memantine differ?

Glutamate is released in excess in cells damaged by Alzheimer's disease. Memantine is a voltagedependent, moderate-affinity, uncompetitive N-methyl-D-asparate (NMDA) receptor antagonist. Memantine blocks the effects of pathologically elevated tonic levels of glutamate, preventing further neuronal dysfunction. 24 6274 7680

ر.	Prescribing Points with memantine ^{24,62,74,76,80}				
-	► Memantine is generally well tolerated and the				
T	incidence of adverse effects is low. Common adverse				
I	effects include: dizziness, headache, constipation,				
Ţ	somnolence and hypertension.				
-	A dose titration over 4 weeks is required.				
l	Caution in patients with epilepsy or a history of				
J	seizures.				
ݱ	Hepatic impairment – avoid in severe impairment.				
	Memantine is renally excreted. Caution therefore				
I	when used in combination with other drugs that are				
Ţ	renally excreted. Ensure renal function tests are up-to-				
+	date and reduce dose in renal impairment as follows: ⁷⁴				
I					
Т	eGFR (ml /min) Dose				

J	eGFR (mL/min)	Dose
J.	30 to 49	10mg daily.
╇╣		If well tolerated after at
1		least 7 days dose can
J		be increased in steps to
뀢		20mg daily
بر	5 to 29	10 mg daily
J	< 5	Avoid



* Memantine: moderate Alzheimer's dementia in those intolerant of or in whom AChE inhibitors are contraindicated. ** Rivastigmine and donepezil are unlicensed in DLB. Rivastigmine is licensed only for mild – moderately severe Alzheimer's dementia and mild – moderately severe dementia in those with idiopathic Parkinson's disease. Donepezil is licensed for the symptomatic treatment of mild to moderately severe Alzheimer's dementia.

TABLE EIGHT: Drug Interactions with dementia drugs 9,73-77

Drugs for dementia	Interacting drugs	Nature of Interaction
Donepezil	Ketoconazole, itraconazole,	Increased plasma level of donepezil through CYP
	erythromycin, quinidine, fluoxetine	3A4/2D6 inhibition
	Rifampicin, phenytoin,	Decreased plasma level of donepezil through
	carbamazepine, alcohol	CYP 3A4/2D6 induction
	Anticholinergics	Antagonistic effect
	Anaesthesia	Additive effect on succinylcholine-type muscle relaxation
	Cholinergic agonists (e.g. bethanecol)	Additive effect
	Bradycardic drugs (e.g. beta	Additive vagotonic effects on heart rate, e.g.
	blockers, digoxin, amiodarone,	bradycardia
	calcium channel antagonists)	,
	Antipsychotics	Increased risk of neuroleptic malignant syndrome
Rivastigmine	Non-hepatic metabolism. Therefore m	
U U	Cocaine	Rivastigmine may inhibit the butyl cholinesterase
		mediated metabolism of other substances
	Anticholinergics	Antagonistic effect
	Anaesthesia	Additive effect on succinylcholine-type muscle
		relaxation
	Cholinergic agonists (e.g. bethanecol)	Additive effect
Galantamine	Ketoconazole, erythromycin,	Increased plasma level of galantamine
	ritonavir, quinidine, paroxetine,	through CYP 3A4/2D6 inhibition
	fluoxetine, fluvoxamine, amitriptyline	
	Anticholinergics	Antagonistic effect. Avoid concomitant use
	Cholinomimetics	Additive effect. Avoid concomitant use
	Bradycardic drugs	Additive vagotonic effects on heart rate
	Drugs that cause torsades de point	Additive effect. ECG recommended
Memantine	Cimetidine, ranitidine, procainamide,	
	Climetioline, ranitidine, procalinamide, quinidine, quinine, nicotine Warfarin Isolated cases of increased INR	
	Drugs that alkalinise urine (e.g. carbonic anhydrase inhibitors, sodium bicarbonate)	Reduce renal elimination of memantine
	Hydrochlorothiazide	Possible reduced level of hydrochlorothiazide
	Levodopa, dopaminergic agonists,	Effects enhanced
	anticholinergics	
	Barbiturates and neuroleptics	Effects of these may be reduced
	Amantadine, ketamine and	Risk of pharmacotoxic psychosis
	dextromethorphan	
	Phenytoin	One published case report on risk
	Dantrolene and baclofen	Dosage adjustment may be necessary
		ther drugs metabolised via CYP 3A4 and 2D6

Management of Behavioural and Psychological Symptoms of Dementia (BPSD)

What are Behavioural and Psychological Symptoms of dementia (BPSD)?

These are non-cognitive symptoms that are generally recognised as being beyond the former "in-character" nature of the person with Alzheimer's disease.⁶⁹ BPSD are common and can be very distressing. BPSD vary in both their presentation and underlying cause.³² These symptoms are often associated with chemical changes in the brain or by social and environmental triggers.⁷ Behavioural problems typically begin with subtle personality changes and progress to increasing lapses of social propriety.^{32,69} They are the largest risk factor for people with dementia entering institutional care.^{31,100}

Symptoms of BPSD?

Prevalence of each type of BPSD varies considerably.⁹⁶ BPSD may be divided into three main syndromes:^{15,31}

- 1) Psychotic symptoms (visual and auditory hallucinations and persecutory delusions)
- Mood disorders (depression, anxiety, apathy)
 Agitation (aggression, irritability,
- restlessness, pacing. Usually associated with distress or anxiety).⁸⁵

These can manifest as:

- Aggression
- Restlessness
- Agitation
- Sleep disturbance (day night reversal)
- Calling out repeatedly/ disruptive vocal activity such as shouting or screaming

- Wandering
- Apathy
- Hoarding
- Cursing
- Sexual disinhibition
- Shadowing.3,15

Incidence of BPSD?

Over 90% of people with dementia develop behavioural problems or psychiatric symptoms at some point during their illness.³¹ BPSD occur most commonly in the middle stage of dementia.¹⁵ Depressive and apathetic symptoms are usually the earliest to appear.¹⁰⁰ Hallucinations, elation/euphoria, and aberrant motor behaviour (inability to sit still) are usually the last symptoms to emerge.¹⁰⁰ Apathy is the most common and persistent symptom (reported in 75% of cases); delusional symptoms are least persistent.¹⁰⁰

The problem with low dose antipsychotics

Low dose antipsychotics have been used historically to manage BPSD. Originally first generation antipsychotics (e.g. haloperidol) were used. Practice later changed to second generation atypical antipsychotics (e.g. risperidone, quetiapine) with a lower incidence of extrapyramidal side effects.⁹ However, antipsychotics (whether typical or atypical) have been shown to have only a limited benefit in managing BPSD. There is also the very real risk of increased mortality and an unfavourable side effect profile.^{18,7} Furthermore, antipsychotics are often continued for long periods of time without review.⁹⁶

Risk of stroke with Antipsychotics

In 2004 the CSM reported on an approximately **threefold increased risk** of stroke compared with placebo with the use of the antipsychotics risperidone or olanzapine in elderly people with dementia. The magnitude of risk outweighs any likely benefit of treating dementia-related behavioural problems.⁴⁴ SPCs for <u>all</u> antipsychotics (atypical and conventional) now carry a warning about possible cerebrovascular risk.⁹

Prescribing Patterns

Often patients are prescribed antipsychotics as a blanket first line approach to manage BPSD, before considering other non-pharmacological approaches, and without adequate monitoring.^{18,34} The government commissioned Banerjee Report (2009) concluded that antipsychotic use was too high

First Line Management Options

- 1) Identify possible trigger factors of BPSD
- 2) Is there an underlying medical problem?
- Can simple non-drug options improve symptoms?
- 4) Watchful waiting

Identify trigger factors

An early and comprehensive assessment to establish the likely factors that may generate, aggravate or improve such behaviour.³ By making simple changes, a significant impact on behavioural symptoms can be seen. in patients with dementia, and that the associated risks outweighed the benefits in most of these patients.

According to the Report, approximately 180,000 people with dementia are treated with antipsychotic medication in England alone per year. Of these people:

- Up to 36,000 may derive some benefit from treatment
 - 1,800 may die
 - 1,620 may suffer a cerebrovascular adverse event (around half of which may be severe)¹⁸

As a result, the government pledged to reduce prescribing of antipsychotics for patients with dementia by two thirds by 2011. Recent prescribing data has shown a positive decrease in the number of elderly patients being prescribed antipsychotics. However, targets have still not been fully met.

Adverse effects of Antipsychotics

- The most common side effects include: • Extrapyramidal side effects (movement
 - Extrapyramidal side effects (movement disorders) such as akathisia or dystonia
 - Anticholinergic effects such as dry mouth, blurred vision and constipation
 - Excessive sedation
 - Feelings of dizziness or light headedness, unsteadiness and falls (potentially leading to fractures)
 - Weight gain
 - Accelerated rate of decline and disease progression in people with dementia, hence there are particular concerns over the long term use of these drugs.³³

More rare, but serious, side effects include:

- Changes to blood sugar levels
- Changes to blood lipid levels
- Increased risk of stroke
- Neuroleptic malignant syndrome (fever, faster breathing, sweating, muscle stiffness and reduced consciousness)
- Severe sensitivity in people with dementia with Lewy bodies, possibly causing death in these individuals
- Changes in ECG which can lead to cardiac arrhythmias.

Many local Trusts have developed behavioural service teams which can be a valuable source of advice.

Physical health problems

Underlying physical health problems are often a cause of BPSD. Treatment of concurrent health problems can therefore lead to resolution of BPSD without the need for other treatment. The time period for emergence of BPSD can sometimes be an indication of cause: sudden emergence of BPSD often has a physical trigger. Longer onset emergence can be linked to depression.⁷ Physical health problems include infection, pain and dehydration.⁸⁴

Infection

Urinary tract infections and chest infections are frequent trigger factors for BPSD. Dental infections are also common but often not recognised.⁸⁴

Undetected pain

Pain is one of the most common causes of BPSD.⁷ Many people with dementia have difficulty in communicating about their pain which can manifest as agitation. Pain is difficult to detect in dementia and hence underdiagnosed.

A prescription of regular simple analgesia such as paracetamol 1g four times a day can be beneficial.^{5,7}

Constipation or urinary retention

Faecal impaction or urinary retention can cause discomfort. Again, many people with dementia have difficulty in communicating this, which can manifest as agitation.⁹⁷

Other potential discomforts

Also consider the following: is the patient too hot? Too cold? Thirsty? Hungry? Do they have pressure sores?

Visual and auditory impairment

This should be treated if possible – change glasses or hearing aid; encourage them to be worn regularly.⁸⁴

Environmental factors

The characteristics of the environment are an important contributory factor to BPSD.³³

A lack of meaningful stimulation can be linked to a high prevalence of BPSD.³³ BPSD are particularly common in care homes. There is a clear need to improve the level of social interaction and stimulation available to care home residents.

People need to engage in <u>constructive</u> activities and interaction. Organised activities need to be tailored to individual needs.

On the other hand, over-stimulation can sometimes cause confusion to the person. Therefore, keeping the environment constant and in line with what the patient has been used to is advised.

Consider is the patient experiencing any of the following:

- Overstimulation
- Under-stimulation
- Unfamiliar people or surroundings (e.g. hospital admission)
- Does the person recognise the environment as home? Does it contain things to help them feel at home?
- Change in daily schedule or routine⁶⁹

Treat the Target Symptoms

There are no adequate drug treatments available for non-cognitive behavioural symptoms at present.¹² BPSDs are potentially treatable however through targeting specific symptoms when considering medication.

1) **Identify** the specific target symptom(s) for the patient: agitation, aggression, irritability, restlessness, pacing, visual/auditory hallucinations, delusions, depression, anxiety, apathy, insomnia?

2) Quantify the symptoms. How severe?

3) Document the target symptom(s).

Customise a treatment plan for the individual patient, based on target symptoms. This plan should be time limited: agree a time frame for review of symptoms with carers and document in the notes.

Individually tailored care plans can then be developed that help carers and staff address the behaviour that

- Is the TV or radio playing something that the person can relate to and enjoy?
- If the person is mobile, can they move around freely and have access to outside space? Could assistive technology be used to improve freedom or safety?

Watchful waiting (or 'Active Monitoring')

Watchful waiting is actually an <u>active</u> process. It involves on-going assessment over a four week period of observing possible contributing factors and reviewing simple non-drug treatments. It does not mean 'doing nothing'. A high proportion of people with dementia who have behavioural and psychological symptoms experience significant improvements over four weeks with no specific treatment. Watchful waiting is the safest and most effective therapeutic approach unless there is severe risk or extreme distress.

Non-pharmacological measures

Non-pharmacological interventions are recommended before initiating drug therapy. Simple adjustments to social interactions and environment can make a difference.⁷

Consider interventions tailored to the person's preferences, skills and abilities. Monitor response and adapt the care plan as needed. Depending on availability, consider options including:

- Aromatherapy
- Reflexology
- Multisensory stimulation
- Therapeutic use of music and/or dancing
- Animal-assisted therapy
- Massage.³

challenges.³ Care plans should focus on round the clock care, i.e. not just on the daytime, when dementia is clearly a 24-hour illness and one in which normal patterns, such as sleeping at night, can become disrupted.³³

4) **Monitor** response to treatment: changes in target symptoms should be assessed and recorded at regular intervals.³

Can Alzheimer's treatments be used for BPSD?

Dementia drugs should be optimised before considering low dose antipsychotics. Indeed, adherence to therapy should be emphasised as a means to reducing risk of BPSD.⁸⁰ People at this stage of dementia are likely to already be receiving an AChE inhibitor for cognition. Dementia drugs would only be tried where behaviours are relatively mild; if the symptoms are severe and distressing or dangerous then antipsychotics may be needed.

AChE inhibitors

Donepezil, rivastigmine and galantamine were developed as symptomatic treatments for dementia and are licensed for the treatment of people with mild-moderate Alzheimer's disease. Evidence suggests that they may also have beneficial effects on behavioural symptoms.³³ It can take several weeks of treatment for effects to become apparent.⁵¹

Memantine

Ongoing RCTs in Canada and in the UK will hopefully clarify the role of memantine in the treatment of agitation/aggression in Alzheimer's disease and vascular dementia.⁸⁵ There is growing evidence to support the use of memantine for treating and preventing the behavioural symptoms of moderate to severe Alzheimer's disease.^{9,59-62} Significant effects were seen as early as week 12.⁶¹ Optimising the management of patients with Alzheimer's disease involves reducing the emergence of new symptoms as well as controlling existing behavioural changes.⁶¹

AChE inhibitors and memantine appear to produce complementary benefits on different types of BPSD – **AChE inhibitors:** appear to reduce depression, anxiety and apathy-related BPSDs while **Memantine:** may reduce symptoms such as agitation, aggression, irritability/lability, and psychosis.⁸⁰

When to consider an Alzheimer's treatment for BPSD?

(If not already receiving treatment) an AChE inhibitor or memantine may be considered if a nonpharmacological approach is inappropriate or has been ineffective and symptoms are causing significant distress or potential harm to the individual.

An AChE inhibitor may be considered for BPSD in:

People with mild to moderate Alzheimer's disease.
 People with Dementia with Lewy Bodies (DLB).
 Rivastigmine has shown reduced core psychiatric symptoms in patients with DLB in some studies.⁷⁸

Memantine may be considered for BPSD in:

1) People with moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors.

2) People with severe Alzheimer's disease.^{3,9,45}

When not to offer an Alzheimer's treatment for BPSD? ^{3,9,45}

Do not offer to people who have purely vascular dementia. An AChE inhibitor or memantine may be *trialled* in people with mixed dementia. Antipsychotics should ideally be avoided in patients with vascular dementia due to risk of stroke.

How to manage depression in dementia?

Evidence shows psychological intervention, such as positive events and exercise, are effective for mild to moderate depression and should be considered first line.^{7,84} However, for more severe depression, antidepressants are considered.^{7,84} If an antidepressant is to be used, drugs with anticholinergic effects (such as tricyclic antidepressants) should be avoided because they may adversely affect cognition.

Pharmacologic treatment for depression should last between 6 and 12 months, with re-evaluation (at least) monthly.⁷⁰ Recent studies suggest that antidepressants may have lower efficacy for depression in Alzheimer's disease.^{12,35}

How to manage sleep disorders in dementia?

Behavioural interventions are generally more effective than pharmacologic ones in cases of insomnia in patients with Alzheimer disease.⁶⁹ Sleep hygiene measures should be adopted. It may help to consider:

- Reducing daytime napping
- Increasing activities during the day (rather than napping)
- Agreeing realistic expectations for sleep duration.⁷

When sleep hygiene measures have failed, short term treatment (4 weeks) with a hypnotic such as zopiclone (3.75 mg/day) or zolpidem (5 mg/day) can be considered. However, this is only supported by anecdotal evidence.⁷

Caution: Benzodiazepines

Benzodiazepines should not <u>routinely</u> be used to manage BPSD or be considered an alternative to antipsychotics due to:

- Limited evidence of benefit
- Association with cognitive decline
- Increased risk of falls/fractures in the elderly.

When to use low dose antipsychotics in the management of BPSD

When to consider an antipsychotic?

NICE recommend that "medication for non-cognitive symptoms or behaviour that challenges should be considered in the first instance only if there is severe distress or an immediate risk of harm to the person with dementia or others. For less severe distress and/or agitation, a non-drug option should be used initially."³ The drug should be administered orally, at the lowest effective dose, for the shortest possible time (ideally no longer than 12 weeks).

Antipsychotics are most helpful in the control of symptoms such as **hallucinations** and **delusional thinking** rather than for agitation or attenuating aggression.⁶⁹ Hallucinations and delusions indicate psychosis and must be distinguished from disorientation, fearfulness and misunderstanding,

which are common in people with dementia.⁹⁷ Symptoms such as restlessness and repetitive vocalisation/shouting out can be the expression of unmet needs.¹² There is no evidence that antipsychotics show benefit for repetitive vocalisation/shouting out.¹⁰⁵

Which antipsychotic should be used?

NICE recommend that if antipsychotic treatment is appropriate, the specific drug should be chosen after an individual risk-benefit analysis, including an analysis of the cerebrovascular risk of the patient. There is evidence to support risperidone and olanzapine in reducing physical aggression, agitation and psychosis.⁴⁴ Quetiapine appears to be widely used in elderly people but there is no evidence to support effectiveness in BPSD and it can cause significant postural hypotension and sedation.⁸² Olanzapine has anticholinergic properties and is associated with rapid and significant weight gain.⁸²

Licensed use of antipsychotics

Risperidone is licensed for: short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer's dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.³⁰ Other than risperidone, use of antipsychotics to manage BPSD is off-label. Service users/carers should be informed of this

Conditions for prescribing an antipsychotic According to NICE, people with Alzheimer's disease, vascular dementia, mixed dementias or DLB with **severe** non-cognitive symptoms: (psychosis and/or agitated behaviour causing significant distress) may be *trialled* with an antipsychotic drug after the following conditions have been met:

- There should be a full discussion with the person with dementia and/or carers about the possible benefits and risks of treatment. In particular, cerebrovascular risk factors should be assessed and the possible increased risk of stroke/transient ischaemic attack and possible adverse effects on cognition discussed.
- Changes in cognition should be assessed and recorded at regular intervals. Alternative medication should be considered if necessary.
- Target symptoms should be identified, quantified and documented.
- Changes in target symptoms should be assessed and recorded at regular intervals.
- The effect of co-morbid conditions, such as depression, should be considered.
- The choice of antipsychotic should be made after an individual risk-benefit analysis; there is no 'preferred choice'.
- Document details of treatment, including medicine name, dose and frequency.
- The dose should be low initially and then titrated upwards.
- Treatment should be time limited and regularly reviewed – at 6 and/or at 12 weeks (according to clinical need).^{3,7}

What is meant by Low Dose?


Antipsychotics have routinely been advised at relatively low doses to manage BPSD. With the exception of risperidone, antipsychotics are not licensed for this indication. In the absence of licensed doses for BPSD, the following doses have been selected from the literature and clinical practice as starting doses:

Review & Stopping antipsychotics

A recent Cochrane Review (2013) concluded that many older people with Alzheimer's disease and BPSD can be withdrawn from chronic antipsychotic medication without detrimental effects on their behaviour.⁹⁶ Discontinuation programmes could be incorporated into routine practice.⁹⁶ All antipsychotic prescriptions should be reviewed at 6 and/or at 12 weeks. The limited evidence for

TABLE NINE: Low doses of antipsychotics

Antipsychotic	Low dose for BPSD
Risperidone	250 micrograms twice daily ⁵⁵
Olanzapine	2.5mg once daily
Aripiprazole	5mg once daily
Quetiapine	12.5mg twice daily



 People with Dementia with Lewy Bodies: Rivastigmine is the first line treatment; this should be tried for several weeks.

An antipsychotic should only be used after **specialist advice**. This is due to the increased risk of neuroleptic malignant syndrome and sensitivity to extrapyramidal side effects of atypical antipsychotics in people with DLB.

antipsychotics for BPSD indicates that on-going treatment offers no benefit over longer periods of therapy.⁸⁵ Therefore treatment should only be continued beyond 12 weeks in exceptional circumstances; discontinuation should be default except in extreme circumstances.^{7,85} Most behavioural complications of dementia are intermittent and do not persist for longer than three months.⁹⁶ 70% of people

COMPASS Therapeutic Notes on the Management of Dementia, June 2013

have no worsening of symptoms when antipsychotics are discontinued.

Patients with a current prescription:

Withdrawal from antipsychotics can be safe in people with dementia who have taken antipsychotics for prolonged periods, especially when symptoms have largely resolved.99

Identify and review patients who have dementia and are on antipsychotics, with the purpose of understanding why antipsychotics have been prescribed. In consultation with the patient, their family and carers, and clinical specialist colleagues such as those in psychiatry, establish: whether the continued use of antipsychotics is appropriate, whether it is safe to begin the process of discontinuing their use; and what access to alternative interventions is available.67

Are withdrawal symptoms a problem?

Possible withdrawal symptoms from antipsychotics include autonomic and behavioural symptoms such as nausea, vomiting, anorexia, rhinorrhoea, diarrhoea, diaphoresis, myalgia, paraesthesia, anxiety, as well as movement disorders, such as withdrawal emergent parkinsonism, withdrawal dyskinesia and covert dyskinesia.9

Consult the best-practice guide from Alzheimer's Society:

http://alzheimers.org.uk/site/scripts/download_info.php ?downloadID=609

TABLE TEN: How to stop an antipsychotic?

Dose of antipsychotic	How to discontinue
If the person is receiving a low dose	Proceed directly with discontinuation. Monitor patient and review at two weeks. ⁷
If the person is receiving a higher dose	Taper the dose over one month – reduce to half dose for 2 weeks, review at 2 weeks, discontinue after a further 2 weeks ⁷

For those with worsening of symptoms after discontinuation

The first four weeks are the most challenging but are often effectively managed with watchful waiting, preventing the need to restart antipsychotics. The risk of recurrence of behavioural and psychiatric symptoms after discontinuation may be more likely if:

- Previous discontinuation has caused symptoms to return
- The person currently has severe symptoms.

If symptoms remain severe (with associated severe risk and/or distress): and further treatment with antipsychotics is considered clinically necessary, a referral to specialist services is advised. Caution is required in residents with more severe symptoms and in people with psychosis or agitation who responded well to antipsychotic medication before. In these people, withdrawal might not be recommended until further evidence becomes available.96

Summary: Good practice points in managing BPSD

- Consider specialist referral in cases of extreme risk or distress.
- Begin management with 'watchful waiting' for 4 weeks (including assessment of medical conditions and pain) and simple non-drug assessment.
- Use specific interventions if symptoms are severe or persist after watchful waiting and simple non-drug treatments:
 - Psychosocial treatments and 0 behavioural interventions.
 - Drug treatment of underlying health 0 disorders (e.g. pain relief, infections) as appropriate.⁷
- Consider a time-limited trial of antipsychotics if specific interventions have been unsuccessful and symptoms are causing extreme distress or risk of harm.
- All people with dementia who are receiving antipsychotic drugs should receive a clinical review from their doctor to ensure that their care is compliant with current best practice and guidelines, and that alternatives to medication have been considered.68

References

- Clinical Knowledge Summaries. Dementia. Accessed 1) 26/2/2013 [http://www.cks.nhs.uk].
- Improving Dementia Services in Northern Ireland, a Regional Strategy, November 2011. NICE. Clinical Guideline CG42, 2006 (amended 2011). 2)
- 3) Dementia: Supporting people with dementia and their carers in health and social care. Accessed 26/2/2013
- [http://www.nice.org.uk/]. NPC. MeReC Rapid Review, 2009, No 847. Government 4) takes action on reducing the use of antipsychotic drugs in dementia. [http://www.npc.nhs.uk].
- NPC. MeReC Rapid Review, 2011, No 4119. Treating pain 5) to reduce behavioural disturbances in people with dementia. [http://www.npc.nhs.uk].
- NPC. MeReC Rapid Review, 2011, No 3471. Providing 6) support for dementia patients and carers [http://www.npc.nhs.uk].
- Alzheimer's Society. Optimising treatment and care for 7) behavioural and psychological symptoms of dementia. Alzheimer's Society Best Practice Guide. July 2011.
- 8) MHRA. CSM letter to healthcare professionals, 2004. Accessed 19/03/2013. [http://www.mhra.gov.uk/Safetyinformation/Safetywarnings afetywarningsandmessagesformedicines alertsandred CON10042981.
- Taylor D, Paton C and Kapur S. The Maudsley, Prescribing 9)
- Guidelines in Psychiatry, 2012. Briesacher BA, Tjia J, Field T, Peterson D, Gurwitz JH. JAMA, 2013;309(5)440-2. Antipsychotic use among nursing 10) home residents.
- Royal College of Psychiatrists. Accessed 26/2/2013 11) [http://www.rcpsych.ac.uk].
- 12)
- Alzheimer's Society. Accessed 27/2/2013 [http://www.alzheimers.org.uk]. National Framework for Action on Dementia 2006-2010; 13) NSW Department of Health on behalf of Australian Health Ministers' Conference (2006)
- Living Fuller Lives; Bamford Review of Mental Health and 14) Learning Disability (Northern Ireland), 2007 Dementia UK The Full Report; LSE, King's College London
- 15) and Alzheimer's Society, 2007
- Health and Social Care Inequalities Monitoring System: Life Expectancy Decomposition An overview of changes in 16) Northern Ireland life expectancy 2001-03 to 2006-08, DHSSPS 2011
- Jorm, AF, Korten, AE & Henderson, AS. The prevalence of 17) dementia: a quantitative integration of the literature. Acta Psychiatrica Scandinavica, 1987;76,465-479.
- The use of antipsychotic medication for people with 18) dementia: Time for Action; Banerjee S; Department of Health (2009).
- Psychiatric illness predicts poor outcome after surgery for 19) hip fracture: a prospective cohort study; Holmes J and House A. Psychological Medicine, 2000; 30(4) 921–929. Counting the Cost: Caring for people with dementia on
- 20) hospital wards; Alzheimer's Society (2009).

- Patterson S M, Hughes C M, Crealey G, Caerdwell C, 21) Lapane K. An evaluation of an adapted United States model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood NI Study). Journal of the American Geriatrics Society 2010; 58: 44-53 Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W.
- 22) Survival following dementia onset: Alzheimer's disease and vascular dementia, J Neurol Sci, 2005;229(30)43–9. 23)
- Lovestone S and Gauthier S. Management of Dementia, 2001. ISBN 1853177393. NICE. Alzheimer's disease – donepezil, galantamine, 24)
- rivastigmine and memantine (TA 217), 2011 [http://www.nice.org.uk/]. Weinmann S, et al. Systematic review of Ginkgo biloba for
- 25) treatment of dementia. BMC Geriatrics, 2010;10:14
- DeKosky ST, et al. Ginkgo in preventing dementia: RCT evidence. JAMA, 2008;300:2253-62. 26)
- Sydenham E, Dangour AD and Lim WS. Omega 3 fatty 27) acid for the prevention of cognitive decline and dementia (Review). Cochrane database Syst Rev, 2012. No.:CD005379.
- Dementia indicators in QoF. QoF 2012/13. Accessed 19/3/2013 [http://www.eguidelines.co.uk]. 28)
- HSCB. Northern Ireland Formulary. Accessed 4/3/2013 [http://www.hscboard.hscni.net/NIFormulary/Chapter%204 29) %20-%20Central%20Nervous%20System%20-%20PDF%201MB.pdf].
- Risperdal tablets Summary of Product Characteristics, last updated on the eMC: 28/11/2012. 30)
- htp://www.medicines.org.uk . Ballard, C, O'Brien, J, Swann, A and James I, (2001) Treating Behavioural and Psychological Symptoms of 31) Dementia. Oxford University Press, Oxford, UK
- Finkel, SI, Costa e Silva, J, Cohen, G, Miller, S and Sartorius, N. Behavioral and psychological signs and 32) symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int. Psychogeriatr, 1996; 8 (Suppl. 3) 497-500. Ballard C and Nurock S. Drugs for behavioural symptoms
- 33) in people with dementia in care facilities. The Journal of Quality Research in Dementia, Issue 1. Accessed 7/3/2013 http://www.alzheimers.org.uk/site/scripts/documents_info.p hp?documentID=77&pageNumber=2]. Furniss, L, Craig, SK and Burns, A. Medication use in
- 34) nursing homes for elderly. Int. J. Ger. Psych., 1998;13, 433-439.
- 35) Banerjee S, J Hellier et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and
- placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess 2013;17(7):1–166 Frances PT et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147. Mesulam M et al. Widely spread butyrylcholinesterase can bydelyter acet debelies in the particular data butyrylcholinesterase can 36)
- 37) hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-93.
- 38) Burns A et al. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's Disease. Int J Geriatr Psychiatry 2007;22:806-812.
- Doody RS et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's Disease. Arch Neurol 2001;58:427-433. 39)
- Singh S et al. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 2003;18:282-40) 284.
- Waldemar G et al. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's Disease. Int J Geriatr Psychiatry 2008;23:979-41) 981
- Dybicz SB et al. Patterns of cholinesterase-inhibitor use in 42) Byolic 25 et al. Patients of choinesterase-initiation dee in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother 2006;4:154-160 Sadowsky CH et al. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in
- 43) patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010;64:188-193.
- MHRA. Antipsychotic drugs, page last modified: 16 March 44) 2012. Accessed 19/3/2013 [http://www.mhra.gov.uk] NICE. Alzheimer's disease - donepezil, galantamine,
- 45) rivastigmine and memantine (TA217), March 2011.
- Accessed 20/03/2013 [http://www.nice.org.uk/]. NICE Pathways. Dementia. Accessed 20/03/2013 46) [http://pathways.nice.org.uk/pathways/dementia].
- 47) Schmitt B et al. combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs 2004;18:827-844.
- Tariot PN et al. memantine treatment in patients with moderate to severe Alzheimer;s disease already receiving 48)

donepezil: a randomized controlled trial. JAMA

- 2004;291:317-324. Hartmann S et al. Tolerability of memantine in combination 49) with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003;18:81-85.
- Atri A et al. Long-term course and effectiveness of 50) combination therapy in Alzheimer's Disease. Alzheimer Dis Assoc Disord 2008;22:209-221.
- Lopez OL et al. Long-term effects of the concomitant use of 51) memantine with cholinesterase inhibition in Alzheimer disease. j Neurol Neurosurg Psychiatry 2009;80:600-607. Periclou AP et al. Lack of pharmacokinetic or
- 52) pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004;38:1389-1394. Grossberg GT et al. Rationale for combination therapy with
- 53) galantamine and memantine in Alzheimer's disease. J Clin Pharmacol 2006;46:17S-26S. Birks J, Grimley Evans J. Ginkgo biloba for cognitive
- 54) impairment and dementia. Cochrane database Syst Rev 2009:1:CD003120.
- Risperdal tablets SPC. Last updated 28/11/2012 55)
- Accessed 21/3/2013 [<u>http://www.medicines.org.uk</u>]. Eyes on Evidence, Feb 2013. Billioti de Gage et al. Benzodiazepine use and risk of 56)
- 57) dementia: prospective population based study. BMJ, 2012 345 e6231
- Kavirajan H et al. Efficacy and adverse effects of 58) cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-792.
- Cummings JL et al. Behavioral effects of memantine in 59) Alzheimer's disease patients receiving donepezil. Neurology 2006;67:57-63.
- Wilcock GK et al. Memenatine for agitation/aggression and 60) psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341-348.
- Gauthier S et al. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by 61) memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-545.
- 62) McShane R et al. Memantine for dementia. Cochrane Database Syst Rev 2006;2:CD003154.
- Verdoux H et al. Is benzodiazepine use a risk factor for cognitive decline in Alzheimer's disease? A literature 63) review of epidemiological studies. Psychol Med 2005;35:307-315.
- Lagnaoui R et al. Benzodiazepine utilization patterns in 64) Alzheimer's disease patients. Pharmacoepidemiol Drug Saf 2003;12:511-515.
- Seitz DP et al. Antidepressants for agitation and psychosis 65) in dementia. Cochrane Database Syst Rev 2011;2:CD008191.
- Personal Communication, Eisai Ltd, March 2012. 66) MHRA. Drug Safety Update, May 2012. Accessed 67)
- 68)
- 25/3/2013 [http://www.mhra.gov.uk]. NPC. Low dose antipsychotics in people with dementia e-learning. Accessed 26/03/2013 [http://www.npc.nhs.uk]. Osborn G and Vaughn Saunders A. Current treatments for patients with Alzheimer disease. J Am Osteopath Assoc. 2010;4/04.02.40210 69)
- 2010;110(9 suppl 8):S16-S26. Lyketsos CG, Colenda CC, Beck C, et al; Task Force of 70) American Association for Geriatric Psychiatry. Position American Association for Genaric Psychiatry. Position statement of the American Association for Geneatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry. 2006;14(7):561-572. Cavan J. Pharmacological Management of BPSD, Good Practice Checklist. Central & North West London NHS Evundation Trust. 2011
- 71) Foundation Trust, 2011. Thaipisuttikul P and Galvin JE. Use of medical foods and
- 72) nutritional approaches in the treatment of Alzheimer's
- disease. Clin Pract (Lond) 2012; 9(2):199–209. EMC. Exelon[®] Summary of Product Characteristics, last 73) updated 30/01/2013 http://www.medicines.org.uk/emc/medicine/1284/SPC/Exel
- 74)
- RPSGB/BMA. BNF 65, March September 2013. EMC. Aricept Tablets[®] Summary of Product Characteristics, last updated 1/02/2013 75) [http://www.medicines.org.uk/emc/medicine/577/SPC/Arice
- <u>pt+Tablets</u>]. EMC. Ebixa[®] Summary of Product Characteristics, last 76) updated 24/05/2013 http://www.medicines.org.uk/emc/medicine/10175/SPC/Ebi
- xa+5mg+pump+actuation+oral+solution%2c+20mg+and+1 0+mg+Tablets+and+Treatment+Initiation+Pack] EMC. Reminyl Tablets[®] Summary of Product Characteristics, last updated 17/07/2012 77) http://www.medicines.org.uk/emc/medicine/10335/SPC/Re
- minul+Tablets]. McKeith IG. Dementia with Lewy Bodies. Br J Psych 78) 2002;180:144-147.

- 79) Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;3:CD006504.
- Alireza A. Effective Pharmacological Management of Alzheimer's Disease. Am J Manag Care 2011;17:S346-S355.
- 81) Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr. 2011 Apr;23(3):372-8.
 82) BPAC. Antipsychotics for Dementia Best Practice Guide .
- 82) BPAC. Antipsychotics for Dementia Best Practice Guide . Accessed 8/04/2013 [http://www.bpac.org.nz/a4d/resources/docs/bpac_A4D_be
- st practice guide.pdf].83)Ballard C and Howard R. Neuroleptic drugs in dementia:
- benefits and harm. Nat Rev Psychiatry 2006;7(6)492-500.
 Ballard C et al. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev
- Psychiatry 2008;20(4)396-404.
 85) Ballard C and Corbett A. Management of Neuropsychiatric Symptoms in People with Dementia. CNS Drugs 2010;24(9)729-739.
- 86) Rasmussen J. Why the Concerns about Using Antipsychotics for People with Dementia? Accessed 22/4/2013 [http://www.surreycare.org.uk/cms/uploads/downloads/olde r%20people/DementiaMasterclass-DrJillRasmussen1.pdf].
- NICE. Quality standard for supporting people to live well with dementia QS30, April 2013 [http://publications.nice.org.uk/quality-standard-for-
- supporting-people-to-live-well-with-dementia-gs30].
 NICE. Delaying the onset of disability, frailty and dementia in later life: scope consultation. Accessed 22/4/2013 [http://guidance.nice.org.uk/PHG/64/ScopeConsultation].
- Alzheimer's Association. Mild Cognitive Impairment. Accessed 22/4/2013 [http://www.alz.org/].
- 90) Busse A et al. Progression of mild cognitive impairment to dementia: a challenge to current thinking. The British Journal of Psychiatry, 2006;189:399-404.
 91) Cancelli I. Anticholinergic drugs increase the risk of
- Cancelli I. Anticholinergic drugs increase the risk of cognitive decline and dementia in older people. Evid Based Mental Health 2010;13:44.
- 92) PL Detail-Document #271206. Drugs with Anticholinergic Activity. Prescriber's Letter 2011; 18(12):271223.
 93) Torjesen T. Anticholinergic effects of common drugs are
- Torjesen T. Anticholinergic effects of common drugs are associated with increased mortality in over 65s. BMJ, 2011; 342:d4037.
- Rudolph JL et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-13.
- 95) Feldman H, Gracon S. Clinical Diagnosis and Management of Alzheimer's disease, 1996:239-253.
 96) Declercq T et al. Withdrawal of chronic antipsychotic drugs
- 96) Declercq T et al. Withdrawal of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane database Syst Rev, 2013. No.:CD007726.pub2.
- The Merck Manual. Behavioral and Psychologic Symptoms of Dementia. Accessed 25/4/2013 [http://www.merckmanuals.com].
- Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. International Journal of Geriatric Psychiatry, 2013; doi:10.1002/gps9346.
- Ballard C et al. A randomised, blinded, placebo controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine 2008;5(4):e76.
- 100) Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2005 Jun;13(6):460-8.
- 2003 Juli, 13(0):400-0.
 Wynn ZJ, Cummings JL: Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's discose. Democrat Corist: Cosp. Disord 2004; 17:100–108.
- disease. Dement Geriatr Cogn Disord 2004; 17:100–108.
 102) Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms of Alzheimer's disease. Curr Treat Optimer Neurol 2012;11(2):112-25
- disease. Curr Treat Options Neurol 2012;14(2):113-25.
 Howard R et al. Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. N Engl J Med 2012; 366:893-903.
- 104) Jones R, Sheehan B, Phillips P, et al. DOMINO-AD protocol: Donepezil and Memantine in Moderate to Severe Alzheimer's Disease – a multicentre randomised controlled trial. Trials 2009;10:57-57.
- 105) SIGN. Scottish Intercollegiate Guidelines Network
- Management of patients with dementia, 2006. 106) Bazire, S. Psychotropic Drug Directory, 2012; p77.

- © Queen's Printer and Controller of HMSO 2012 This material was prepared on behalf of the Northern Ireland Health and Social Care Board by: Michelle Bradley MPharm MSc MPS
- Medicines Management Information Pharmacist COMPASS Unit
- Pharmaceutical Department
- NI Health and Social Care Board
- 2 Franklin Street, Belfast
- BT2 8DQ.

You may re-use this material free of charge in any format or medium for private research/study, or for circulation within an organisation, provided that the source is appropriately acknowledged. The material must be re-used accurately in time and context, and must NOT be used for the purpose of advertising or promoting a particular product or service for personal or corporate gain.

Any queries on re-use should be directed to Michelle Bradley (e-mail michelle.bradley@hscni.net, telephone 028 9053 5661)

Please note that every effort has been made to ensure that the content of the COMPASS Therapeutic Notes is accurate at the time of publication. Readers are reminded that it is their responsibility to keep up-to-date with any changes in practice.

With thanks to the following for kindly reviewing this document:

- Dr David Craig, Consultant Geriatrician, Northern Health and Social Care Trust
- Mr Andrew Dawson, Clinical Pharmacist, Southern Health and Social Care Trust
- Professor Peter Passmore, Professor of Ageing and Geriatric Medicine, Queen's University, Belfast

 Dr Stephen Todd, Consultant Geriatrician, Western Health and Social Care Trust

- Dr Maura Young, Consultant in Old Age Psychiatry, Northern Health and Social Care Trust
- The editorial panel for this edition of the COMPASS
- Therapeutic Notes:

Dr Bryan Burke (General Practitioner)

- Miss Veranne Lynch (Medicines Management Advisor, Belfast LCG)
- Dr Thérèse Rafferty (Medicines Management Information Analyst, HSCBSO)
- Mrs Stephanie Sloan (Community Pharmacist)



COMPASS THERAPEUTIC NOTES ASSESSMENT Management of Dementia

COMPASS Therapeutic Notes are circulated to GPs, nurses, pharmacists and others in Northern Ireland. Each issue is compiled following the review of approximately 250 papers, journal articles, guidelines and standards documents. They are written in question and answer format, with summary points and recommendations on each topic. They reflect local, national and international guidelines and standards on current best clinical practice. Each issue is reviewed and updated every three years.

Each issue of the Therapeutic Notes is accompanied by a set of assessment questions. These can contribute 2 hours towards your CPD/CME requirements. Submit your completed MCQs to the appropriate address (shown below) or complete online (see below). Assessment forms for each topic can be submitted in **any order** and at **any time**.

If you would like extra copies of Therapeutic Notes and MCQ forms for this and any other topic you can: Visit the COMPASS Web site: <u>www.medicinesni.com</u> or <u>www.hscbusiness.hscni.net/services/2163.htm</u> or

Email your requests to: compass.team@hscni.net or

Phone the COMPASS Team on: 028 9053 5661

You can now complete your COMPASS multiple choice assessment questions and print off your completion certificate online:

Doctors and nurses should submit their answers at: www.medicinesni.com

Pharmacists should submit their answers at: www.nicpld.org

Are you a					
Pharmacist? 🗌 Community 🗌 Hospital 🗌 Other (please specify)					
GP? Enter your cipher number:					
Nurse? Enter your PIN number:					
Title: Mr/Mrs/Miss/Ms/Dr					
Surname:First name:					
Address:					
Postcode:					
GPs and Nurses: Complete the form overleaf and return to: COMPASS Unit Pharmaceutical Department HSC Business Services Organisation 2 Franklin Street Belfast BT2 8DQ					
Pharmacists: Complete the form overleaf and return to: Northern Ireland Centre for Pharmacy Learning & Development FREEPOST NICPLD Belfast BT9 7BL					



For copies of the Therapeutic Notes and assessment forms for this and any other topic please visit: <u>www.medicinesni.com</u> or <u>www.hscbusiness.hscni.net/services/2163.htm</u>.

Successful completion of these assessment questions equates with **2 hours** Continuing Professional Development time. Circle your answer TRUE (T) or FALSE (F) for each question. When completed please post this form to the relevant address shown overleaf. Alternatively, you can submit your answers online:

Doctors and nurses should submit their answers at: <u>www.medicinesni.com</u>

Pharmacists should submit their answers at: <u>www.nicpld.org</u>

а	Dementia is part of normal ageing	Т	F
b	Vascular dementia is more common in smokers and patients with heart disease, hypertension, diabetes or high cholesterol	Т	F
	Opportunistic screening should be carried out in patients at increased risk of		
С	dementia, e.g. patients with Down's syndrome	Т	F
	Patients with symptoms of mild cognitive impairment do not need to be		
d	assessed for dementia	Т	F
2 In relat	ion to risk factors for dementia:		
	It is thought that delaying the onset of dementia in the population by five years	_	_
а	could halve its prevalence	Т	F
	Smoking is thought to be a risk factor for vascular dementia but not Alzheimer's	-	_
b	disease	Т	F
С	Advancing age is the biggest risk factor for dementia	Т	F
d	Vascular dementia is more common in women than men	Т	F
a b	Weight loss is a reported side effect and the patient's weight should be monitored People who have neither improved significantly or declined further within	T T	F
	3 months treatment should be discontinued	T	F
С	Dose titration regimens are used to minimise side effects	I	г
d	Acetylcholinesterase inhibitors should be switched in patients who show loss of benefit several years after initiation of treatment	Т	F
	ion to management of Behavioural and Psychological Symptoms of tia (BPSD):		
a	Drug treatment should be targeted to the symptoms	Т	F
b	Memantine is often added to existing acetylcholinesterase inhibitor therapy to manage behavioural symptoms	Т	F
С	Antidepressants are considered first line treatment option for depression	Т	F
d	Benzodiazepines should be considered a routine treatment option.	Ť	F
u		1	
5 In relat	ion to low dose antipsychotics for the management of BPSD:		
а	Low dose antipsychotics are first line treatment option	Т	F
b	It is OK to continue for long periods of time without review	Т	F
С	Studies have shown on-going treatment offers no benefit over longer periods (more than 12 weeks)	Т	F
d	Quetiapine is the only drug licensed for short term management	Т	F